Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Triple Doublet Therapy in Newly Diagnosed Müllerian Carcinoma
NCT00157560Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2000
- Primary completion
- Nov 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, gemcitabine, paclitaxel, doxorubicin and topotecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Massachusetts General Hospital. Primary endpoint: Laparotomy Defined Response Rate. Started Dec 2000; status: completed.
02
Drugs
carboplatingemcitabinepaclitaxeldoxorubicintopotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00157560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157560.